📣 VC round data is live. Check it out!

PetMeds Valuation Multiples

Discover revenue and EBITDA valuation multiples for PetMeds and similar public comparables like Talea Group, Autopedia, 111, YES24 and more.

PetMeds Overview

About PetMeds

PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.


Founded

1996

HQ

United States

Employees

173

Financials (LTM)

Revenue: $179M
EBITDA: ($35M)

EV

$25M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PetMeds Financials

PetMeds reported last 12-month revenue of $179M and negative EBITDA of ($35M).

In the same LTM period, PetMeds generated ($35M) in EBITDA losses and had net loss of ($47M).

Revenue (LTM)


PetMeds P&L

In the most recent fiscal year, PetMeds reported revenue of $179M and EBITDA of ($22M).

PetMeds is unprofitable as of last fiscal year, with gross margin of 28%, EBITDA margin of (12%), and net margin of (32%).

See analyst estimates for PetMeds
LTMLast FY202320242025202620272028
Revenue$179M$179M$275M$240M$191M
Gross Profit-$50M$77M$72M$55M
Gross Margin-28%28%30%29%
EBITDA($35M)($22M)($301K)$5M($15M)
EBITDA Margin(20%)(12%)(0%)2%(8%)
EBIT Margin(26%)(18%)(2%)(1%)(12%)
Net Profit($47M)($57M)($6M)($7M)($45M)
Net Margin(26%)(32%)(2%)(3%)(23%)

Financial data powered by Morningstar, Inc.

PetMeds Stock Performance

PetMeds has current market cap of $46M, and enterprise value of $25M.

Market Cap Evolution


PetMeds' stock price is $2.13.

PetMeds share price decreased by 1.4% in the last 30 days, and by 35.8% in the last year.

PetMeds has an EPS (earnings per share) of $-2.68.

See more trading valuation data for PetMeds
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$25M$46M-1.4%-1.4%-6.6%-35.8%$-2.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PetMeds Valuation Multiples

PetMeds trades at 0.1x EV/Revenue multiple, and (0.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for PetMeds

EV / Revenue (LTM)


PetMeds Financial Valuation Multiples

As of June 3, 2026, PetMeds has market cap of $46M and EV of $25M.

PetMeds has a P/E ratio of (1.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.1x0.1x0.1x0.1x0.1x
EV/EBITDA(0.7x)(1.1x)(82.2x)5.2x(1.7x)
EV/EBIT(0.5x)(0.8x)(3.8x)(10.8x)(1.0x)
EV/Gross Profit-0.5x0.3x0.3x0.4x
P/E(1.0x)(0.8x)(8.2x)(6.9x)(1.0x)
EV/FCF-(0.7x)4.5x(71.7x)(1.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PetMeds Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PetMeds Margins & Growth Rates

PetMeds grew revenue by 1% but EBITDA decreased by 152% in the last fiscal year.

In the most recent fiscal year, PetMeds reported gross margin of 28%, EBITDA margin of (12%), and net margin of (32%).

See estimated margins and future growth rates for PetMeds

PetMeds Margins

Last FY202420252026202720282029
Gross Margin28%30%29%28%
EBITDA Margin(12%)2%(8%)2%
EBIT Margin(18%)(1%)(12%)(4%)
Net Margin(32%)(3%)(23%)(7%)
FCF Margin(18%)(0%)(13%)(18%)

PetMeds Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth1%(13%)(21%)(6%)
Gross Profit Growth-(7%)(23%)(9%)
EBITDA Growth(152%)(1682%)(412%)(121%)
EBIT Growth(106%)(65%)933%(72%)
Net Profit Growth(103%)19%578%(70%)
FCF Growth-(106%)7110%33%

Data powered by FactSet, Inc. and Morningstar, Inc.

PetMeds Operational KPIs

PetMeds' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.

PetMeds' Rule of 40 is (4%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PetMeds' Rule of X is (13%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PetMeds
LTMLast FY202320242025202620272028
Rule of 40(19%)(4%)---
Bessemer Rule of X(17%)(13%)---
Revenue per Employee-$1.0M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue-12%8%10%12%
G&A Expenses to Revenue-28%20%18%25%
Opex to Revenue-46%30%31%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PetMeds Competitors

PetMeds competitors include Talea Group, Autopedia, 111, YES24, Delticom, Grove Collaborative, Mister Spex, BlueMTec, CarParts.com and Brillia Inc.

Most PetMeds public comparables operate across Consumer E-commerce, Pet Care, Pharmacies, Vertical E-commerce and PetTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Talea Group0.6x-24.4x-
Autopedia0.5x-4.6x-
1110.0x-(0.0x)-
YES240.3x-132.9x-
Delticom0.2x0.2x5.3x5.3x
Grove Collaborative0.5x0.5x(39.7x)(918.8x)
Mister Spex0.2x0.2x(1.4x)(6.0x)
BlueMTec0.5x-79.9x-

This data is available for Pro users. Sign up to see all PetMeds competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PetMeds

When was PetMeds founded?PetMeds was founded in 1996.
Where is PetMeds headquartered?PetMeds is headquartered in United States.
How many employees does PetMeds have?As of today, PetMeds has over 173 employees.
Who is the CEO of PetMeds?PetMeds' CEO is Leslie C.G. Campbell.
Is PetMeds publicly listed?Yes, PetMeds is a public company listed on Nasdaq.
What is the stock symbol of PetMeds?PetMeds trades under PETS ticker.
When did PetMeds go public?PetMeds went public in 1997.
Who are competitors of PetMeds?PetMeds main competitors include Talea Group, Autopedia, 111, YES24, Delticom, Grove Collaborative, Mister Spex, BlueMTec, CarParts.com, Brillia Inc.
What is the current market cap of PetMeds?PetMeds' current market cap is $46M.
What is the current revenue of PetMeds?PetMeds' last 12 months revenue is $179M.
What is the current revenue growth of PetMeds?PetMeds revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of PetMeds?Current revenue multiple of PetMeds is 0.1x.
Is PetMeds profitable?No, PetMeds is not profitable.
What is the current EBITDA of PetMeds?PetMeds has negative EBITDA and is not profitable.
What is PetMeds' EBITDA margin?PetMeds' last 12 months EBITDA margin is (20%).
What is the current EV/EBITDA multiple of PetMeds?Current EBITDA multiple of PetMeds is (0.7x).
How many companies PetMeds has acquired to date?PetMeds hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies PetMeds has invested to date?PetMeds hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to PetMeds

Lists including PetMeds

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial